Charles Schwab
VYNT

Charles Schwab’s Vyant Bio, Inc. Common Stock VYNT Stock Holding History

Charles Schwab’s Portfolio VYNT Stock Details VYNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,609
Closed -$49K – 3564
2021
Q2 		$49K Buy
+2,609
New +$48.6K ﹤0.01% 3376

Other funds holding VYNT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BF
Blankinship & Foster Solana Beach, California $452M AUM 16.63% 1-Year Est. Return
FWM
Frontier Wealth Management Kansas City, Missouri $1.38B AUM 6.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Cerity Partners
Cerity Partners New York $70.8B AUM 21.68% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TWMP
Taylor Wealth Management Partners Boston, Massachusetts $176M AUM 14.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab's VYNT Position: Q3 2021 in Review

Charles Schwab sold out of Vyant Bio, Inc. Common Stock (VYNT) in Q3 2021, closing a stake of 2,609 shares — an estimated $49K sold.

Charles Schwab first reported a position in VYNT in Q2 2021 and held it in 1 quarter. The position peaked at $49K in Q2 2021. 23 funds tracked by Wall St. Rank hold VYNT as of Q3 2021.

  • Charles Schwab reported no remaining Vyant Bio, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Charles Schwab sold 2,609 Vyant Bio, Inc. Common Stock shares in Q3 2021, an estimated $49K.
  • Charles Schwab first reported a position in Vyant Bio, Inc. Common Stock in Q2 2021 and held it in 1 quarter.
  • Charles Schwab's Vyant Bio, Inc. Common Stock position peaked at $49K in Q2 2021.
  • 23 funds tracked by Wall St. Rank held Vyant Bio, Inc. Common Stock as of Q3 2021.

Based on Charles Schwab's 13F filing for Q3 2021, filed 16 Nov 2021.